News and Trends 3 Aug 2022 Deciphering the molecular mechanisms of severe COVID-19 Researchers from Fujita Health University School of Medicine in Japan have been investigating COVID-19 to lead to therapeutic options against the severe form of the condition. Levels of proinflammatory cytokines are dramatically elevated in severe COVID-19 patients, the molecular mechanisms of which remain unclear. In a recent article in mBio, the researchers elucidated the role […] August 3, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 Chinese biotech Sironax closes $200M funding round Sironax, an emerging Chinese biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases, has completed $200 million in series B financing. The round was led by Gaorong Capital and Yunfeng Capital, with participation from existing investors including Temasek, Invus, F-Prime Capital, Eight Roads, ARCH Venture Partners, […] August 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 3 Aug 2022 Orca Bio announces Precision-T phase 3 study open and enrolling patients across US transplant centers US-based Orca Bio, today announced Precision-T, its pivotal phase 3 study, is open, enrolling and treating 174 leukemia patients at more than 20 clinical trial sites. Precision-T is a randomized, open-label multi-center study that is evaluating the safety and efficacy of Orca Bio’s lead investigational high-precision cell therapy, Orca-T, compared to standard of care allogeneic […] August 3, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 siRNA company Eleven Therapeutics seals $22M funding Eleven Therapeutics has raised a total of $22 million in seed funding. Among the roster of funders is the Bill & Melinda Gates Foundation, which committed $9 million in funding to Eleven, including $5 million towards future equity investment supporting the development of a first-of-its-kind platform that designs small interfering RNAs (siRNAs) with ultra-long durability […] August 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 3 Aug 2022 The biggest European biotech investments in July 2022 The mRNA firm Normax Biomed snagged Europe’s biggest private biotech investment in July 2022, with runners-up including AgomAb and Tropic Biosciences. Life sciences manufacturing companies saw a big windfall in Europe in July 2022 as the Cork-based Normax Biomed bagged around $301 million. The firm is establishing modular manufacturing facilities that could provide mRNA vaccines […] August 3, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 Enrollment completed for trial looking at treatment of diabetic kidney disease Enrollment has been completed for a study of a regenerative cell therapy investigational product for intra-renal artery administration to treat diabetic kidney disease (DKD). U.S.-based Caladrius Biosciences Inc., a clinical-stage biopharma company that develops therapies designed to treat or reverse disease, made the announcement today (August 2). The phase 1b open-label, proof-of-concept study will look […] August 2, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 New monkeypox tracing method can analyze multiple samples and quickly detect virus strains Dutch company Molecular Biology Systems (MBS), in collaboration with Amsterdam University Medical Center, and researchers from the Danish Rigshospitalet, has developed a fast typing method to trace monkeypox. The new method, NextGenPCR, not only detects strains of the virus quickly, it allows for analysis of multiple samples simultaneously. This way, the inventors say, genetic characterization […] August 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 Success across the board for C4X Discovery Holdings plc and its partnerships Drug discovery company C4X Discovery Holdings plc released a report today (August 2) detailing the continued success of its relationship with partners across its portfolio. The company says it is happy to report it received its first milestone payment last month of €3 million ($3.1 million) from Sanofi under the out-licensing agreement for its IL-17A […] August 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 MAIA Biotechnology raises $10M from public offering U.S. clinical stage company MAIA Biotechnology, Inc. has closed its initial public offering of 2,000,000 shares of the company’s common stock at a public offering price of $5.00 per share. The gross proceeds from the initial public offering were $10 million, prior to deducting underwriting discounts, commissions, and other offering expenses. The company has granted […] August 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 2 Aug 2022 The evolving arsenal against mosquito-borne diseases Genetic engineering is breaking new ground in the control of mosquito-borne diseases. However, a genetic engineering approach isn’t the only option, as many biotech companies aim to prove. As the global climate continues to warm, disease-spreading mosquitoes such as Aedes aegypti are expected to establish themselves in the U.S. and Europe. This could result in […] August 2, 2022 - 8 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 IDRx launches with $122M to treat cancer with precision combination therapies DRx, Inc., a clinical-stage biopharmaceutical company, launched today with a $122 million oversubscribed series A financing. The financing was led by Andreessen Horowitz (a16z) and Casdin Capital, with participation from Nextech Invest, Forge Life Science Partners and other undisclosed investors. Inspired by a few curative combination regimens in cancer and the successful drug cocktails engineered […] August 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 FDA gives ok to Krystal Biotech cystic fibrosis clinical trial U.S. company Krystal Biotech is set to start a clinical trial for cystic fibrosis after the United States Food and Drug Administration (FDA) accepted its investigational new drug (IND) application. The gene therapy company will be evaluating KB407, a modified HSV-1 vector carrying two copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to […] August 2, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email